[go: up one dir, main page]

WO2004061408A3 - Utilisation d’un inhibiteur non specifique du recepteur 5ht2b pour le traitement du cancer de la prostate - Google Patents

Utilisation d’un inhibiteur non specifique du recepteur 5ht2b pour le traitement du cancer de la prostate Download PDF

Info

Publication number
WO2004061408A3
WO2004061408A3 PCT/FR2003/003878 FR0303878W WO2004061408A3 WO 2004061408 A3 WO2004061408 A3 WO 2004061408A3 FR 0303878 W FR0303878 W FR 0303878W WO 2004061408 A3 WO2004061408 A3 WO 2004061408A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
prostate cancer
specific inhibitor
5ht2b receptor
5ht2b
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2003/003878
Other languages
English (en)
Other versions
WO2004061408A2 (fr
Inventor
Alain Latil
Laurent Chene
Serge Grisoni
Hugues Bienayme
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Urogene SA
Original Assignee
Urogene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urogene SA filed Critical Urogene SA
Priority to AU2003303568A priority Critical patent/AU2003303568A1/en
Publication of WO2004061408A2 publication Critical patent/WO2004061408A2/fr
Publication of WO2004061408A3 publication Critical patent/WO2004061408A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Utilisation d’un inhibiteur non spécifique interagissant avec le récepteur 5HT2B, avantageusement la ritansérine, pour la fabrication d’un médicament destiné au traitement du cancer de la prostate.
PCT/FR2003/003878 2002-12-26 2003-12-23 Utilisation d’un inhibiteur non specifique du recepteur 5ht2b pour le traitement du cancer de la prostate Ceased WO2004061408A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003303568A AU2003303568A1 (en) 2002-12-26 2003-12-23 Use of a non-specific inhibitor of the 5ht2b receptor for the treatment of prostate cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR02/16699 2002-12-26
FR0216699A FR2849382A1 (fr) 2002-12-26 2002-12-26 Utilisation du gene htr2b pour le traitement du cancer de la prostate

Publications (2)

Publication Number Publication Date
WO2004061408A2 WO2004061408A2 (fr) 2004-07-22
WO2004061408A3 true WO2004061408A3 (fr) 2004-08-19

Family

ID=32480198

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/FR2003/003878 Ceased WO2004061408A2 (fr) 2002-12-26 2003-12-23 Utilisation d’un inhibiteur non specifique du recepteur 5ht2b pour le traitement du cancer de la prostate
PCT/FR2003/003875 Ceased WO2004060390A2 (fr) 2002-12-26 2003-12-23 Utilisation d'un inhibiteur specifique du recepteur 5ht2b pour le traitement du cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/003875 Ceased WO2004060390A2 (fr) 2002-12-26 2003-12-23 Utilisation d'un inhibiteur specifique du recepteur 5ht2b pour le traitement du cancer

Country Status (3)

Country Link
AU (2) AU2003299399A1 (fr)
FR (1) FR2849382A1 (fr)
WO (2) WO2004061408A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009023299A2 (fr) * 2007-04-13 2009-02-19 Southern Research Institute Agents anti-angiogéniques et procédés d'utilisation
US11034751B1 (en) 2018-01-30 2021-06-15 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating cancer using serotonin receptor inhibitors
EP4408397A4 (fr) * 2021-09-30 2025-08-13 Nat Centre For Cell Science Nouvelle combinaison d'un antagoniste du récepteur (5-htr) de la sérotonine et d'un immunomodulateur et de médicaments chimiothérapeutiques pour l'inhibition du cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0727206A2 (fr) * 1995-01-17 1996-08-21 Pfizer Inc. Utilisation de la Sertraline pour le traitement des malades du cancer
FR2810677A1 (fr) * 2000-06-27 2001-12-28 Urogene Procede de diagnostic in vitro du cancer de la prostate et kit de mise en oeuvre
WO2002043652A2 (fr) * 2000-11-29 2002-06-06 Ramot At Tel-Aviv University Ltd. Medicaments anti-proliferation
US6444477B1 (en) * 2000-11-28 2002-09-03 Pharmagene Laboratories Limited Assay method for detecting 5-HT2B antagonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958934A (en) * 1996-05-23 1999-09-28 Syntex (U.S.A.) Inc. Aryl pyrimidine derivatives and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0727206A2 (fr) * 1995-01-17 1996-08-21 Pfizer Inc. Utilisation de la Sertraline pour le traitement des malades du cancer
FR2810677A1 (fr) * 2000-06-27 2001-12-28 Urogene Procede de diagnostic in vitro du cancer de la prostate et kit de mise en oeuvre
US6444477B1 (en) * 2000-11-28 2002-09-03 Pharmagene Laboratories Limited Assay method for detecting 5-HT2B antagonists
WO2002043652A2 (fr) * 2000-11-29 2002-06-06 Ramot At Tel-Aviv University Ltd. Medicaments anti-proliferation

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ABDUL M ET AL: "GROWTH-INHIBITORY EFFECTS OF SEROTONIN UPTAKE INHIBITORS ON HUMAN PROSTATE CARCINOMA CELL LINES", JOURNAL OF UROLOGY, BALTIMORE, MD, US, vol. 154, 1 July 1995 (1995-07-01), pages 247 - 250, XP000574488, ISSN: 0022-5347 *
BARNES NICHOLAS M ET AL: "A review of central 5-HT receptors and their function", NEUROPHARMACOLOGY, vol. 38, no. 8, August 1999 (1999-08-01), pages 1083 - 1152, XP002286166, ISSN: 0028-3908 *
HOYER D ET AL: "VII. INTERNATIONAL UNION OF PHAMACOLOGY CLASSIFICATION OF RECEPTORS FOR 5-HYDROXYTRYPTAMINE (SEROTONIN)", PHARMACOLOGICAL REVIEWS, WILLIAMS AND WILKINS INC., BALTIMORE, MD,, US, vol. 46, no. 2, 1 June 1994 (1994-06-01), pages 157 - 203, XP000604197, ISSN: 0031-6997 *
S C SWEETMAN: "Martindale, The complete drug reference", 2002, THE PHARMACEUTICAL PRESS, LONDON, UK, XP002286238 *
SERAFEIM ADAMANTIOS ET AL: "5-Hydroxytryptamine drives apoptosis in biopsylike Burkitt lymphoma cells: Reversal by selective serotonin reuptake inhibitors.", BLOOD, vol. 99, no. 7, 1 April 2002 (2002-04-01), April 1, 2002, pages 2545 - 2553, XP002253203, ISSN: 0006-4971 *
TUTTON P J M ET AL: "INFLUENCE OF INHIBITORS OF SEROTONIN UPTAKE ON INTESTINAL EPITHELIUM AND COLORECTAL CARCINOMAS", BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 46, no. 2, 1 August 1982 (1982-08-01), pages 260 - 265, XP000574489, ISSN: 0007-0920 *

Also Published As

Publication number Publication date
AU2003299399A8 (en) 2004-07-29
AU2003303568A8 (en) 2004-07-29
WO2004060390A3 (fr) 2004-08-19
FR2849382A1 (fr) 2004-07-02
WO2004060390A2 (fr) 2004-07-22
AU2003303568A1 (en) 2004-07-29
AU2003299399A1 (en) 2004-07-29
WO2004061408A2 (fr) 2004-07-22

Similar Documents

Publication Publication Date Title
AUPS054702A0 (en) Cancer therapy
WO2003080582A3 (fr) Derives de fredericamycine
AU2003224076A1 (en) Antibody combination useful for tumor therapy
TW200603818A (en) Conjugates of hydroxyethyl starch and erythropoietin
AU2001282717A1 (en) Cancer treatment by combination therapy
WO2007127263A3 (fr) Utilisations thérapeutiques d'urolithines
IL182423A0 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
IL164599A0 (en) Combination therapy for the treatment of cancer
WO2007020103A3 (fr) Nouvelle utilisation de composes peptidiques pour traiter une douleur musculaire
MX2007003108A (es) Compuestos imidazo-3-il-amina sustituidos y biciclicos.
MX2007002470A (es) Fenilaminotiazoles sustituidos y su uso.
WO2003039539A3 (fr) Utilisation d'antagonistes du recepteur de l'endotheline dans le traitement de maladies tumorales
EP1594433A3 (fr) Sensibilisant d'une therapie de cancer
NZ593381A (en) Prophylactic/therapeutic agent for cancer comprising a metastin derivative
IL178261A0 (en) Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
AU2003302822A1 (en) Antibodies to treat cancer
WO2004061408A3 (fr) Utilisation d’un inhibiteur non specifique du recepteur 5ht2b pour le traitement du cancer de la prostate
AU2003223538A1 (en) Methods for the treatment of cancer
EG23393A (en) Production of olefins.
WO2004054497A3 (fr) Utilisation d'une substance activant trpm8 pour traiter des tumeurs
AU2003224603A1 (en) Potentiation of cancer therapies by znf217 inhibition
AU2003283339A1 (en) Cancer therapy determination
EP2029615B8 (fr) Procédé de préparation d'un oxaliplatine
AU2003231803A1 (en) Treatment of cancer with mefloquire
AU2003282709A8 (en) Gene expression profiling of bladder cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP